Given the preferential activation of STAT5 in EGFRvIII-expressing cells and its role in GBM proliferation, we used pimozide to inhibit STAT5 in mice orthotopically implanted with GBM6, an EGFRvIII+ patient-derived xenograft. Here, STAT5B is linked to glioblastoma.